Equities analysts expect that Stryker Co. (NYSE:SYK) will report sales of $3.20 billion for the current quarter, according to Zacks. Ten analysts have issued estimates for Stryker’s earnings, with the highest sales estimate coming in at $3.24 billion and the lowest estimate coming in at $3.15 billion. Stryker posted sales of $2.96 billion in the same quarter last year, which suggests a positive year over year growth rate of 8.1%. The company is scheduled to report its next earnings results on Tuesday, April 24th.
On average, analysts expect that Stryker will report full-year sales of $3.20 billion for the current financial year, with estimates ranging from $13.32 billion to $13.67 billion. For the next year, analysts anticipate that the firm will report sales of $14.40 billion per share, with estimates ranging from $14.22 billion to $14.56 billion. Zacks’ sales calculations are an average based on a survey of research firms that cover Stryker.
Stryker (NYSE:SYK) last issued its quarterly earnings results on Tuesday, January 30th. The medical technology company reported $1.96 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.95 by $0.01. Stryker had a return on equity of 24.56% and a net margin of 8.20%. The firm had revenue of $3.47 billion for the quarter, compared to analyst estimates of $3.42 billion. During the same period in the previous year, the company posted $1.78 earnings per share. The company’s quarterly revenue was up 9.9% compared to the same quarter last year.
In other Stryker news, VP William E. Berry, Jr. sold 1,306 shares of the company’s stock in a transaction on Thursday, February 1st. The stock was sold at an average price of $164.42, for a total transaction of $214,732.52. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, Director Howard E. Cox, Jr. sold 7,400 shares of the company’s stock in a transaction on Friday, February 2nd. The stock was sold at an average price of $164.09, for a total value of $1,214,266.00. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 20,390 shares of company stock worth $3,324,962. 7.40% of the stock is owned by corporate insiders.
A number of large investors have recently bought and sold shares of the business. Geode Capital Management LLC lifted its holdings in Stryker by 2.8% during the 4th quarter. Geode Capital Management LLC now owns 3,159,538 shares of the medical technology company’s stock worth $488,110,000 after buying an additional 85,614 shares in the last quarter. Jensen Investment Management Inc. lifted its holdings in Stryker by 0.3% during the 4th quarter. Jensen Investment Management Inc. now owns 2,478,958 shares of the medical technology company’s stock worth $383,842,000 after buying an additional 6,482 shares in the last quarter. Lazard Asset Management LLC lifted its holdings in Stryker by 15.5% during the 4th quarter. Lazard Asset Management LLC now owns 2,208,379 shares of the medical technology company’s stock worth $341,945,000 after buying an additional 296,550 shares in the last quarter. Legal & General Group Plc lifted its holdings in Stryker by 2.8% during the 3rd quarter. Legal & General Group Plc now owns 1,805,572 shares of the medical technology company’s stock worth $256,393,000 after buying an additional 49,143 shares in the last quarter. Finally, Wells Fargo & Company MN lifted its holdings in Stryker by 4.8% during the 3rd quarter. Wells Fargo & Company MN now owns 1,742,959 shares of the medical technology company’s stock worth $247,536,000 after buying an additional 79,551 shares in the last quarter. 74.99% of the stock is currently owned by hedge funds and other institutional investors.
Stryker (SYK) opened at $166.41 on Friday. Stryker has a 12 month low of $129.29 and a 12 month high of $170.00. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.59 and a current ratio of 2.29. The stock has a market capitalization of $62,344.18, a PE ratio of 25.64, a P/E/G ratio of 2.39 and a beta of 0.70.
The firm also recently declared a quarterly dividend, which will be paid on Monday, April 30th. Investors of record on Thursday, March 29th will be given a dividend of $0.47 per share. The ex-dividend date is Wednesday, March 28th. This represents a $1.88 dividend on an annualized basis and a yield of 1.13%. Stryker’s dividend payout ratio (DPR) is presently 70.15%.
COPYRIGHT VIOLATION WARNING: “$3.20 Billion in Sales Expected for Stryker Co. (SYK) This Quarter” was posted by Ticker Report and is the property of of Ticker Report. If you are accessing this story on another site, it was illegally copied and republished in violation of international copyright law. The correct version of this story can be accessed at https://www.tickerreport.com/banking-finance/3255137/3-20-billion-in-sales-expected-for-stryker-co-syk-this-quarter.html.
Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.